

S3 Table. Change in number of users of drugs used to treat MS symptoms two years before and after first LDN prescription by number of LDN dispenses. Three groups based on number of LDN dispenses: LDN x 1 (N=67) collected LDN once, LDN x 2-3 (N=63) two or three times and LDN x 4+ (N=211) four or more times.

	ATC code	Group	Users before LDN		Users after LDN		Change prevalent users		
			N	(%)	N	(%)	%	95% CI	p
Antibiotics	J01	LDN x1	40	59.7	40	59.7	0.0	(-14.3 to 14.3)	0.399
		LDN x 2-3	34	54.0	37	58.7	4.8	(-12.0 to 21.5)	0.341
		LDN x 4+	117	55.5	116	55.0	-0.5	(-8.4 to 7.5)	0.396
Drugs for urinary frequency and incontinence	G04B D	LDN x1	17	25.4	14	20.9	-4.5	(-10.9 to 2.0)	0.158
		LDN x 2-3	17	27.0	15	23.8	-3.2	(-11.9 to 5.6)	0.310
		LDN x 4+	53	25.1	65	30.8	5.7	(1.0 to 10.4)	0.023
Drugs used for constipation	A06	LDN x1	4	6.0	6	9.0	3.0	(-4.1 to 10.1)	0.285
		LDN x 2-3	6	9.5	7	11.1	1.6	(-8.7 to 12.0)	0.381
		LDN x 4+	14	6.6	17	8.1	1.4	(-1.7 to 4.5)	0.265
Drugs used in erectile dysfunction	G04 BE	LDN x1	8	11.9	10	14.9	3.0	(-1.1 to 7.1)	0.142
		LDN x 2-3	5	7.9	4	6.3	-1.6	(-4.7 to 1.5)	0.240
		LDN x 4+	23	10.9	19	9.0	-1.9	(-4.8 to 1.0)	0.178
Methenamine	J01X X05	LDN x1	9	13.4	11	16.4	3.0	(-2.8 to 8.8)	0.240
		LDN x 2-3	9	14.3	10	15.9	1.6	(-5.4 to 8.5)	0.361
		LDN x 4+	32	15.2	31	14.7	-0.5	(-3.8 to 2.9)	0.384
Benzodiazepine related drugs	N05C F	LDN x1	20	29.9	25	37.3	7.5	(-1.1 to 16.1)	0.094
		LDN x 2-3	21	33.3	23	36.5	3.2	(-6.6 to 13.0)	0.326
		LDN x 4+	58	27.5	63	29.9	2.4	(-1.9 to 6.6)	0.219
Benzodiazepines	N05 CD	LDN x1	1	1.5	2	3.0	1.5	(-1.4 to 4.4)	0.240
		LDN x 2-3	2	3.2	2	3.2	0.0	(-4.4 to 4.4)	0.399
		LDN x 4+	4	1.9	2	0.9	-0.9	(-2.3 to 0.4)	0.145
Antidepressants (except TCA)	N06A	LDN x1	13	19.4	14	20.9	1.5	(-6.2 to 9.2)	0.371
		LDN x 2-3	18	28.6	22	34.9	6.3	(-2.3 to 15.0)	0.142
		LDN x 4+	46	21.8	44	20.9	-0.9	(-5.5 to 3.6)	0.367
Opioids	N02A	LDN x1	24	35.8	31	46.3	10.4	(-4.0 to 24.9)	0.145
		LDN x 2-3	19	30.2	26	41.3	11.1	(-1.4 to 23.6)	0.088
		LDN x 4+	69	32.7	50	23.7	-9.0	(-16.0 to -2.0)	0.017
Other analgesics and antipyretics	N02B	LDN x1	20	29.9	24	35.8	6.0	(-3.2 to 15.1)	0.176
		LDN x 2-3	29	46.0	25	39.7	-6.3	(-17.0 to 4.3)	0.202
		LDN x 4+	61	28.9	74	35.1	6.2	(0.9 to 11.4)	0.029
NSAIDs	M01A	LDN x1	33	49.3	30	44.8	-4.5	(-17.2 to 8.2)	0.314
		LDN x 2-3	30	47.6	30	47.6	0.0	(-13.2 to 13.2)	0.399
		LDN x 4+	104	49.3	87	41.2	-8.1	(-15.0 to -1.1)	0.030
Tricyclic antidepressants	N06A A	LDN x1	12	17.9	10	14.9	-3.0	(-10.1 to 4.1)	0.285
		LDN x 2-3	10	15.9	11	17.5	1.6	(-6.6 to 9.8)	0.371
		LDN x 4+	21	10.0	21	10.0	0.0	(-4.4 to 4.4)	0.399
Gabapentin	N03A X12	LDN x1	16	23.9	8	11.9	-11.9	(-20.7 to -3.1)	0.012
		LDN x 2-3	8	12.7	6	9.5	-3.2	(-11.9 to 5.6)	0.310
		LDN x 4+	41	19.4	37	17.5	-1.9	(-7.1 to 3.4)	0.311
Pregabalin	N03A X16	LDN x1	10	14.9	10	14.9	0.0	(-8.3 to 8.3)	0.399
		LDN x 2-3	7	11.1	10	15.9	4.8	(-2.1 to 11.6)	0.158
		LDN x 4+	20	9.5	17	8.1	-1.4	(-5.3 to 2.4)	0.306
Cannabinoids	N02B G10	LDN x1	3	4.5	5	7.5	3.0	(-2.8 to 8.8)	0.240
		LDN x 2-3	3	4.8	4	6.3	1.6	(-3.8 to 7.0)	0.337
		LDN x 4+	11	5.2	22	10.4	5.2	(1.5 to 9.0)	0.010

Change in prevalent users as proportion (%) of entire group \pm 95 % confidence interval.